| 130 | 0 | 82 |
| 下载次数 | 被引频次 | 阅读次数 |
纤维化是由组织损伤或炎症引起的进行性瘢痕形成的过程，可导致器官损伤和衰竭。肠道的纤维化与炎性肠病特别是克罗恩病密切相关。30%的克罗恩病（CD）患者会因纤维化而造成肠道狭窄，导致肠管切除。目前，尚无预防或逆转纤维化抑制肠道狭窄的药物，内镜扩张术和外科手术治疗是主要手段，但复发率很高。只有在纤维化发生的早期确诊并干预才有可能逆转纤维化进程，避免肠道狭窄的产生。然而，炎症和纤维化在受损的肠段中不同程度地共存，有效鉴别诊断炎症和纤维化对治疗策略的选择非常重要。横断面成像技术如磁共振小肠造影、计算机断层扫描小肠造影和肠道超声，用于评估小肠和CD相关并发症（包括狭窄），有望鉴别狭窄中的炎症和纤维化程度以选择最佳疗法。目前，钆剂增强延迟显像和磁化转移磁共振成像，以及超声弹性成像是评估CD患者纤维化的重要工具。本文拟回顾纤维化的无创成像技术，例如扩散加权和磁化转移成像、应变弹性成像、剪切波成像和正电子发射断层扫描，以指导CD患者的治疗决策。
Abstract：Fibrosis is a progressive process induced by tissue damage or inflammation that can lead to various organ failure. 30% of patients with Crohn's disease(CD) develop fibrotic intestinal strictures. There are no effective drugs to prevent or reverse the progression of fibrosis-induced stricture. The intestinal stricture is usually treated by endoscopic dilatation and surgery with high rates of recurrence. With early diagnosis and intervention, fibrosis may be reversed resulting in inhibition of intestinal stricture. Because of varying degrees of inflammation and fibrosis in the damaged bowel segment, it is very important to differentiate fibrosis from inflammation for treatment planning. Magnetic resonance enterography(MRE), computed tomography enterography(CTE), and bowel ultrasound(US)have been performed to assess small bowel and CD-related complications such as strictures. We review diffusion-weighted and magnetization transfer MR imaging, strain elastography, shear-wave imaging, and positron emission tomography for treatment planning in CD patients with intestinal fibrosis and stricture.
[1]Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis, 2002,8(4):244-250.
[2]Rieder F. The gut microbiome in intestinal fibrosis:environmental protector or provocateur? Sci Transl Med, 2013,5(190):190 ps10.
[3]Rieder F, Fiocchi C, Rogler G. Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases. Gastroenterology, 2017,152(2):340-350.e6.
[4]Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture:a multicentre, prospective, observational cohort(CREOLE)study. Gut, 2018,67(1):53-60.
[5]de Bruyn JR, Becker MA, Steenkamer J, et al. Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn’s disease. PLoS One, 2018,13(1):e0190999.
[6]Holvoet T, Devriese S, Castermans K, et al. Treatment of intestinal fibrosis in experimental inflammatory bowel disease by the pleiotropic actions of a local Rho kinase inhibitor.Gastroenterology, 2017,153(4):1054-1067.
[7]Panés J, Bouzas R, Chaparro M, et al. Systematic review:the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther, 2011,34(2):125-145.
[8]Rieder F, Bettenworth D, Imai J, Inagaki Y. Intestinal fibrosis and liver fibrosis:consequences of chronic inflammation or independent pathophysiology? Inflamm Intest Dis, 2016,1(1):41-49.
[9]Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn’s disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis, 2011,17(4):984-993.
[10]Rieder F, Latella G, Magro F, et al. European Crohn’s and colitis organisation topical review on prediction, diagnosis and management of fibrostenosing Crohn’s disease. J Crohns Colitis,2016,10(8):873-885.
[11]Higgins PD. Measurement of fibrosis in Crohn’s disease strictures with imaging and blood biomarkers to inform clinical decisions. Dig Dis, 2017,35(1-2):32-37.
[12]Pellino G, Pallante P, Selvaggi F. Novel biomarkers of fibrosis in Crohn’s disease. World J Gastrointest Pathophysiol, 2016,7(3):266-275.
[13]Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016:part 2:surgical management and special situations. J Crohns Colitis, 2017,11(2):135-149.
[14]Chiorean MV, Sandrasegaran K, Saxena R, et al. Correlation of CT enteroclysis with surgical pathology in Crohn’s disease. Am J Gastroenterol, 2007,102(11):2541-2550.
[15]Li XH, Liang D, Meng JX, et al. Development and validation of a novel computed-tomography enterography radiomic approach for characterization of intestinal fibrosis in Crohn’s disease.Gastroenterology, 2021,160(7):2303-2316.e11.
[16]Fornasa F, Benassuti C, Benazzato L. Role of magnetic resonance enterography in differentiating between fibrotic and active inflammatory small bowel stenosis in patients with Crohn’s disease. J Clin Imaging Sci, 2011,1:35.
[17]Wagner M, Ko HM, Chatterji M, et al. Magnetic resonance imaging predicts histopathological composition of ileal Crohn’s disease. J Crohns Colitis, 2018,12(6):718-729.
[18]Oto A, Zhu F, Kulkarni K, et al. Evaluation of diffusionweighted MR imaging for detection of bowel inflammation in patients with Crohn’s disease. Acad Radiol, 2009,16(5):597-603.
[19]Freiman M, Perez-Rossello JM, Callahan MJ, et al. Characterization of fast and slow diffusion from diffusion-weighted MRI of pediatric Crohn’s disease. J Magn Reson Imaging, 2013,37(1):156-163.
[20]Seo N, Park SH, Kim KJ, et al. MR enterography for the evaluation of small-bowel inflammation in Crohn disease by using diffusion-weighted imaging without intravenous contrast material:a prospective noninferiority study. Radiology, 2016, 278(3):762-772.
[21]Pouillon L, Laurent V, Pouillon M, et al. Diffusion-weighted MRI in inflammatory bowel disease. Lancet Gastroenterol Hepatol,2018,3(6):433-443.
[22]Tielbeek JA, Ziech ML, Li Z, et al. Evaluation of conventional,dynamic contrast enhanced and diffusion weighted MRI for quantitative Crohn’s disease assessment with histopathology of surgical specimens. Eur Radiol, 2014,24(3):619-629.
[23]Moy MP, Sauk J, Gee MS. The role of MR enterography in assessing Crohn’s disease activity and treatment response.Gastroenterol Res Pract, 2016,2016:8168695.
[24]Li XH, Mao R, Huang SY, et al. Characterization of degree of intestinal fibrosis in patients with Crohn disease by using magnetization transfer MR imaging. Radiology, 2018,287(2):494-503.
[25]Groshar D, Bernstine H, Stern D, et al. PET/CT enterography in Crohn disease:correlation of disease activity on CT enterography with18F-FDG uptake. J Nucl Med, 2010,51(7):1009-1014.
[26]Shyn PB, Mortele KJ, Britz-Cunningham SH, et al. Low-dose18F-FDG PET/CT enterography:improving on CT enterography assessment of patients with Crohn disease. J Nucl Med, 2010,51(12):1841-1848.
[27]Saboury B, Salavati A, Brothers A, et al. FDG PET/CT in Crohn’s disease:correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging, 2014,41(4):605-614.
[28]Palatka K, Kacska S, Lovas S, et al. The potential role of FDG PET-CT in the characterization of the activity of Crohn’s disease,staging follow-up and prognosis estimation:a pilot study. Scand J Gastroenterol, 2018,53(1):24-30.
[29]Pellino G, Nicolai E, Catalano OA, et al. PET/MR versus PET/CT imaging:impact on the clinical management of small-bowel Crohn’s disease. J Crohns Colitis, 2016,10(3):277-285.
[30]Catalano OA, Gee MS, Nicolai E, et al. Evaluation of quantitative PET/MR enterography biomarkers for discrimination of inflammatory strictures from fibrotic strictures in Crohn disease. Radiology, 2016,278(3):792-800.
基本信息:
中图分类号:R656.7
引用信息:
[1]李周雷,谭婉红,孟霁昕,等.分子影像学与纤维化（四）：肠纤维化显像之一[J].影像诊断与介入放射学,2022,31(02):139-142.